Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

AIE regimen

A regimen consisting of cytarabine (Ara-C), idarubicin and etoposide, used as an induction treatment for pediatric acute myeloid leukemia (AML). High-dose cytarabine/etoposide/idarubicin regimen may be used for the treatment of AML.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	AraC-idarubicin-etoposide regimen cytarabine-idarubicin-etoposide regimen MRC AML10 study-AIE regimen
Abbreviation:	AIE ICE

AIE regimen

Search NCI's Drug Dictionary